PATH in eye of Indian storm after panel reports HPV vaccine trial irregularities
This article was originally published in Scrip
Executive Summary
Another damning report by an Indian parliamentary panel on clinical trials, this time with scathing comments against the US non-profit organization PATH over the conduct of studies concerning human papillomavirus (HPV) vaccines, could potentially have serious implications for Merck & Co's Gardasil and GlaxoSmithKline's Cervarix vaccines in the country.